Moderate Intensity Exercise and Phenylketonuria
Primary Purpose
Phenylketonuria, PKU
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Acute Moderate Intensity Exercise
Sponsored by
About this trial
This is an interventional basic science trial for Phenylketonuria focused on measuring Phenylketonuria, PKU, Exercise, Muscle Protein Synthesis, Plasma Phenylalanine concentration
Eligibility Criteria
Inclusion Criteria:
- plasma phenylalanine concentration of >1200 micromols at diagnosis
- treated by dietary phenylalanine restriction from early infancy
- willing to participate in this study
- stable BMI of 20-25 for the past 3 months
- currently in average to good physical fitness condition
- physically active 3-4 days per week
Exclusion Criteria:
- previously or are currently taking approved or experimental pharmacologic treatments (i.e.: Biopterin (BH4), sapropterin dihydrochloride (Kuvan), Large Neutral Amino Acids (LNAA), pegylated phenylalanine ammonia lyase (PEG-PAL))
- recent history of weight loss
- endocrine disorder
- pregnant
- anemic
- involved in any other study or research protocol
- participation in a current strength training or performance training regimen
Sites / Locations
- Oregon Health and Science University
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Active Comparator
Arm Label
Sedentary Visit
Exercise Visit
Arm Description
Subjects will do quiet, sedentary activities for 8 hours. Hourly blood draws and breath sampling will be collected. Bolus C13-Lysine will be given at hour 4.
Subjects will do quiet, sedentary activities until hour 5. Blood and breath samples will be collected. At hour 4, subject will consume a bolus of C13-Lysine and immediately walk on a treadmill at a moderate intensity (exercise at 75% of max heart rate) for 45 minutes.
Outcomes
Primary Outcome Measures
Compare plasma phenylalanine concentration of final blood draw during exercise versus sedentary visits.
Compare the final blood sample for phenylalanine concentration from each arm of the study.
Secondary Outcome Measures
Breath Enrichment of C13-Lysine during sedentary and exercise
Compare the AUC total breath enrichment of C13-Lysine during the sedentary and exercise arms.
Full Information
NCT ID
NCT01904708
First Posted
May 31, 2013
Last Updated
October 15, 2014
Sponsor
Oregon Health and Science University
1. Study Identification
Unique Protocol Identification Number
NCT01904708
Brief Title
Moderate Intensity Exercise and Phenylketonuria
Official Title
The Effects of an Acute Bout of Moderate Intensity Exercise on Plasma Amino Acids in Subjects With Phenylketonuria
Study Type
Interventional
2. Study Status
Record Verification Date
October 2014
Overall Recruitment Status
Terminated
Why Stopped
Current design not able to measure the outcomes anticipated.
Study Start Date
May 2013 (undefined)
Primary Completion Date
June 2014 (Actual)
Study Completion Date
June 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oregon Health and Science University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Phenylketonuria (PKU), an inherited genetic disorder, can cause irreversible brain damage, declined executive function, and autistic tendencies unless a phenylalanine (Phe) restricted diet is consistently maintained throughout life. Promoting anabolism, the uptake of free amino acids from the extracellular space, is a key component to maintaining plasma phenylalanine concentrations within treatment range among patients with PKU. Exercise promotes muscle protein synthesis and anabolism, but the effect on blood phenylalanine concentrations in patients with PKU has not been reported.
Our objective is to assess the impact of an acute bout of moderate intensity exercise on protein oxidation and plasma amino acid concentrations, as a potential adjunctive therapy for patients with PKU.
The investigators hypothesize that moderate intensity exercise decreases amino acid oxidation, increases muscle protein synthesis, and promotes tissue uptake of essential amino acids, thereby lowering plasma phenylalanine concentrations in patients with Phenylketonuria.
Detailed Description
The indicator amino acid oxidation technique utilizes a carbon labeled isotope (L-[13C]) tracer that is ingested orally and is measured in expired breath. This method is based on the theory that if one essential amino acid is deficient, all other amino acids will be oxidized until a break-point is reached and at that time all amino acids will be incorporated into muscle protein synthesis. Using a randomized crossover design the investigators plan to investigate the effects of an acute bout of moderate intensity treadmill exercise versus sedentary activities on plasma amino acids in four subjects with PKU. The long-term goal of this novel research is to determine if exercise could be used as an adjunctive therapy to improve the management of plasma phenylalanine levels and promote a normal, healthy quality of life among patients with PKU.
Patient Recruitment: Four post-pubertal participants ranging from 14-17 years of age with classical phenylketonuria (PKU), treated at Oregon Health & Science University, will participate in this pilot study. Participants will be recruited during their routine clinic visit at Doernbecher Children's Hospital Metabolic clinic.
Study Design: This randomized crossover clinical trial will compare the effects of moderate intensity exercise and sedentary activities on amino acid oxidation and plasma amino acid pools using the indicator amino acid oxidation technique. Each participant will be studied on two separate occasions over a one-month period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Phenylketonuria, PKU
Keywords
Phenylketonuria, PKU, Exercise, Muscle Protein Synthesis, Plasma Phenylalanine concentration
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sedentary Visit
Arm Type
No Intervention
Arm Description
Subjects will do quiet, sedentary activities for 8 hours. Hourly blood draws and breath sampling will be collected. Bolus C13-Lysine will be given at hour 4.
Arm Title
Exercise Visit
Arm Type
Active Comparator
Arm Description
Subjects will do quiet, sedentary activities until hour 5. Blood and breath samples will be collected. At hour 4, subject will consume a bolus of C13-Lysine and immediately walk on a treadmill at a moderate intensity (exercise at 75% of max heart rate) for 45 minutes.
Intervention Type
Other
Intervention Name(s)
Acute Moderate Intensity Exercise
Intervention Description
Moderate intensity exercise by walking on a treadmill at 75% of max heart rate.
Primary Outcome Measure Information:
Title
Compare plasma phenylalanine concentration of final blood draw during exercise versus sedentary visits.
Description
Compare the final blood sample for phenylalanine concentration from each arm of the study.
Time Frame
up to 8 hours
Secondary Outcome Measure Information:
Title
Breath Enrichment of C13-Lysine during sedentary and exercise
Description
Compare the AUC total breath enrichment of C13-Lysine during the sedentary and exercise arms.
Time Frame
Hours 1-8 of the study day from each arm.
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
14 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
plasma phenylalanine concentration of >1200 micromols at diagnosis
treated by dietary phenylalanine restriction from early infancy
willing to participate in this study
stable BMI of 20-25 for the past 3 months
currently in average to good physical fitness condition
physically active 3-4 days per week
Exclusion Criteria:
previously or are currently taking approved or experimental pharmacologic treatments (i.e.: Biopterin (BH4), sapropterin dihydrochloride (Kuvan), Large Neutral Amino Acids (LNAA), pegylated phenylalanine ammonia lyase (PEG-PAL))
recent history of weight loss
endocrine disorder
pregnant
anemic
involved in any other study or research protocol
participation in a current strength training or performance training regimen
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Melanie Gillingham, PhD, RD
Organizational Affiliation
Oregon Health and Science University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Oregon Health and Science University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Moderate Intensity Exercise and Phenylketonuria
We'll reach out to this number within 24 hrs